FN2 Earnings Intelligence
West Pharmaceutical Services, Inc. income statement
West Pharmaceutical Services, Inc. (WST) Income Statement (annual) derived from persisted SEC financial facts.
Key Stats
USD in millions, except per-share values and percentages.
| Metric | 12/31/2021 | 12/31/2022 | 12/31/2023 | 12/31/2024 | 12/31/2025 | 12/31/2026 est. | 12/31/2027 est. |
|---|---|---|---|---|---|---|---|
| Market Cap | - | - | - | - | - | - | - |
| - Cash | $762.6 | $894.3 | $853.9 | $484.6 | $791.3 | - | - |
| + Debt | - | - | - | - | - | - | - |
| Enterprise Value | - | - | - | - | - | - | - |
| Revenue | $2,831.6 | $2,886.9 | $2,949.8 | $2,893.2 | $3,074.1 | $3,371.4 | $3,579.3 |
| % Growth | 31.9% | 2.0% | 2.2% | -1.9% | 6.3% | 9.7% | 6.2% |
| Gross Profit | $1,175.8 | $1,136.2 | $1,129.2 | $998.5 | $1,104 | - | - |
| % Margin | 41.5% | 39.4% | 38.3% | 34.5% | 35.9% | - | - |
| EBITDA | $874.6 | $854.6 | $813.3 | $725.3 | $756.3 | - | - |
| % Margin | 30.9% | 29.6% | 27.6% | 25.1% | 24.6% | - | - |
| Net Income | $661.8 | $585.9 | $593.4 | $492.7 | $493.7 | - | - |
| % Margin | 23.4% | 20.3% | 20.1% | 17.0% | 16.1% | - | - |
| Diluted EPS | $8.67 | $7.73 | $7.88 | $6.69 | $6.79 | $8.94 | $9.95 |
| % Growth | 89.7% | -10.8% | 1.9% | -15.1% | 1.5% | 31.7% | 11.3% |
| Operating Cash Flow | $584 | $724 | $776.5 | $653.4 | $754.8 | - | - |
| CapEx | $253.4 | $284.6 | $362 | $377 | $285.9 | - | - |
| Free Cash Flow | $330.6 | $439.4 | $414.5 | $276.4 | $468.9 | - | - |
Historical market capitalization is not persisted, so Market Cap and Enterprise Value remain unavailable rather than mixing today's market value into prior periods.
Income Statement
USD in millions, except per-share values and percentages.
| Metric | 12/31/2021 | 12/31/2022 | 12/31/2023 | 12/31/2024 | 12/31/2025 | 12/31/2026 est. | 12/31/2027 est. |
|---|---|---|---|---|---|---|---|
| Revenue | $2,831.6 | $2,886.9 | $2,949.8 | $2,893.2 | $3,074.1 | $3,371.4 | $3,579.3 |
| Gross Profit | $1,175.8 | $1,136.2 | $1,129.2 | $998.5 | $1,104 | - | - |
| EBITDA | $874.6 | $854.6 | $813.3 | $725.3 | $756.3 | - | - |
| Net Income | $661.8 | $585.9 | $593.4 | $492.7 | $493.7 | - | - |
| Diluted EPS | $8.67 | $7.73 | $7.88 | $6.69 | $6.79 | $8.94 | $9.95 |
Balance Sheet
USD in millions, except per-share values and percentages.
| Metric | 12/31/2021 | 12/31/2022 | 12/31/2023 | 12/31/2024 | 12/31/2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | $762.6 | $894.3 | $853.9 | $484.6 | $791.3 |
| Short-term Debt | - | - | - | - | - |
| Long-term Debt | $208.8 | $206.7 | $72.8 | $202.6 | $202.8 |
| Total Debt | - | - | - | - | - |
Cash Flow
USD in millions, except per-share values and percentages.
| Metric | 12/31/2021 | 12/31/2022 | 12/31/2023 | 12/31/2024 | 12/31/2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | $584 | $724 | $776.5 | $653.4 | $754.8 |
| Capital Expenditure | $253.4 | $284.6 | $362 | $377 | $285.9 |
| Free Cash Flow | $330.6 | $439.4 | $414.5 | $276.4 | $468.9 |
Ratios
USD in millions, except per-share values and percentages.
| Metric | 12/31/2021 | 12/31/2022 | 12/31/2023 | 12/31/2024 | 12/31/2025 |
|---|---|---|---|---|---|
| Revenue Growth | 31.9% | 2.0% | 2.2% | -1.9% | 6.3% |
| Gross Margin | 41.5% | 39.4% | 38.3% | 34.5% | 35.9% |
| EBITDA Margin | 30.9% | 29.6% | 27.6% | 25.1% | 24.6% |
| Net Margin | 23.4% | 20.3% | 20.1% | 17.0% | 16.1% |
| FCF Margin | 11.7% | 15.2% | 14.1% | 9.6% | 15.3% |
| Diluted EPS Growth | 89.7% | -10.8% | 1.9% | -15.1% | 1.5% |